Exfoliative Dermatitis / Erythroderma — VA Disability Rating (DC 7817)

Diagnostic Code 7817 · 38 CFR §4.118

What Is It?

Erythroderma — historically called exfoliative dermatitis — is generalized inflammation and scaling of essentially the entire skin surface. It is not a diagnosis so much as a state: psoriasis, eczema, drug reactions, and cutaneous T-cell lymphoma can all progress into it. When the skin fails across that much area it stops doing its jobs, and the systemic consequences follow: fluid loss, protein loss through shed scale, inability to hold body temperature, high-output cardiac strain, and vulnerability to serious infection. Fever, weight loss, and hypoproteinemia are the markers the regulation names. DC 7817 is the only diagnostic code in the entire skin schedule that reaches 100 percent, and its criteria were rewritten in the 2018 revision around two axes: the duration of systemic therapy, and — at the top two levels — whether generalized involvement is accompanied by systemic manifestations and whether prescribed treatment has documented failure. Understanding those two concepts is the whole game at this code.

Rating Criteria

Evidence Needed

Three categories of evidence decide this claim. First, the extent: documentation that involvement is generalized, ideally with body-surface-area figures and photographs, since the 60 and 100 percent criteria both require generalized disease. Second, systemic manifestations: recorded fevers, a documented weight trend, and laboratory evidence of hypoproteinemia or low albumin — these are what separate 60 percent from 100 percent, and they are laboratory and vital-sign facts that either exist in the chart or do not. Third, therapy: a complete systemic treatment history with durations, plus — critically — documentation of any regimen that was tried and failed. A failed regimen is defined by the regulation as disease progression or less than 25 percent improvement after four weeks, so the record needs a start date, a four-week assessment, and a statement of the response. Hospital admissions for erythroderma are strong evidence of severity throughout.

C&P Exam Tips

Ask the examiner to state explicitly whether involvement is generalized and to record body-surface-area percentage. Bring the laboratory record — albumin and total protein, any documented fevers, and a weight history — because systemic manifestations are the gate to 100 percent and an examiner will not order labs at a C&P appointment. Bring the full treatment history and, for each regimen that did not work, the dates it was started and stopped and what the treating physician wrote about the response. Say the words "treatment failure" and identify how many regimens have failed; two or more is an independent path to 100 percent that does not require systemic manifestations. Describe the day-to-day reality — the temperature intolerance, the shedding, the sleep loss, the infections.

How to File

File on VA Form 21-526EZ as erythroderma or exfoliative dermatitis under DC 7817, and identify the underlying disease if one is known. Attach hospital records, dermatology notes, photographs, laboratory results showing albumin and protein levels, a weight history, and a treatment log naming each regimen with its start date, stop date, and documented response. If the erythroderma arose from a medication prescribed for a service-connected condition, file it as a secondary claim. Claim the complications separately — recurrent infections, nutritional deficiency, and any cardiac strain are ratable under their own codes.

Common Mistakes

The most common mistake is failing to document treatment failure, which is an independent route to the two highest evaluations and the one most often missed. The regulation gives a precise definition — disease progression or less than 25 percent improvement after four weeks of prescribed therapy — and a chart that simply moves from one drug to another without recording why does not establish it. Ask a treating dermatologist to write the failures up explicitly. The second mistake is not obtaining the laboratory evidence of systemic manifestations, without which the claim tops out at 60 percent. The third is arguing the pre-2018 criteria, which were built around itching, exfoliation, and hyperpigmentation; the current code is built around therapy duration, systemic manifestations, and treatment failure. The fourth is being rated on the underlying disease code alone when erythroderma is present, since DC 7817 reaches 100 percent and DC 7806 and DC 7816 stop at 60.

Frequently Asked Questions

What counts as a "systemic manifestation" for the 100 percent rating?

The regulation names fever, weight loss, and hypoproteinemia as examples. These are objective findings, so the evidence is vital-sign records showing documented fevers, a charted weight trend showing loss, and laboratory results showing low total protein or albumin. Without at least one documented systemic manifestation the code caps at 60 percent unless two or more prescribed regimens have documented failure, which is the alternative path to 100 percent.

What is "documented treatment failure"?

The regulation defines it as disease progression, or less than 25 percent improvement in the extent or severity of the condition, after four weeks of a prescribed therapy — and it must be documented. One failed regimen supports 60 percent; two or more support 100 percent. This is why the treatment record should show, for each drug, when it started, what the response was at four weeks, and why it was stopped.

Is erythroderma the same as exfoliative dermatitis?

Yes — erythroderma is the current term and exfoliative dermatitis the older one, and the 2018 revision of the rating schedule adopted the newer name for DC 7817. Both describe generalized inflammatory involvement of essentially the whole skin surface with widespread scaling and shedding. Older decisions and older medical records use the two interchangeably.

Should I be rated under DC 7817 or under my underlying skin disease?

Under whichever produces the higher evaluation, and DC 7817 usually does when erythroderma is genuinely present, because it is the only skin code that reaches 100 percent. Psoriasis (DC 7816) and dermatitis (DC 7806) both stop at 60. If your psoriasis or eczema has progressed to generalized erythroderma, ask expressly that DC 7817 be considered and make sure the record uses the word.